0000000000687600

AUTHOR

Annette B. Vogel

0000-0002-9940-5379

showing 3 related works from this author

A Trans-amplifying RNA Vaccine Strategy for Induction of Potent Protective Immunity

2019

Here, we present a potent RNA vaccine approach based on a novel bipartite vector system using trans-amplifying RNA (taRNA). The vector cassette encoding the vaccine antigen originates from an alphaviral self-amplifying RNA (saRNA), from which the replicase was deleted to form a transreplicon. Replicase activity is provided in trans by a second molecule, either by a standard saRNA or an optimized non-replicating mRNA (nrRNA). The latter delivered 10- to 100-fold higher transreplicon expression than the former. Moreover, expression driven by the nrRNA-encoded replicase in the taRNA system was as efficient as in a conventional monopartite saRNA system. We show that the superiority of nrRNA- ov…

Translational efficiencyGenetic VectorsRNA-dependent RNA polymeraseHemagglutinin (influenza)Hemagglutinin Glycoproteins Influenza VirusBiologyAntibodies ViralMadin Darby Canine Kidney CellsMice03 medical and health sciencesDogsImmunogenicity VaccineInfluenza A Virus H1N1 Subtype0302 clinical medicineOrthomyxoviridae InfectionsCricetinaeInfluenza HumanDrug DiscoveryGeneticsAnimalsHumansViral Replicase Complex ProteinsRepliconMolecular BiologyGene030304 developmental biologyPharmacologyMice Inbred BALB C0303 health sciencesMessenger RNAVaccinationRNATranslation (biology)Antibodies NeutralizingSemliki forest virusVirologyHEK293 CellsInfluenza Vaccines030220 oncology & carcinogenesisbiology.proteinRNA ViralMolecular MedicineFemaleOriginal ArticleMolecular Therapy
researchProduct

BNT162b vaccines are immunogenic and protect non-human primates against SARS-CoV-2

2020

AbstractA safe and effective vaccine against COVID-19 is urgently needed in quantities sufficient to immunise large populations. We report the preclinical development of two BNT162b vaccine candidates, which contain lipid-nanoparticle (LNP) formulated nucleoside-modified mRNA encoding SARS-CoV-2 spike glycoprotein-derived immunogens. BNT162b1 encodes a soluble, secreted, trimerised receptor-binding domain (RBD-foldon). BNT162b2 encodes the full-length transmembrane spike glycoprotein, locked in its prefusion conformation (P2 S). The flexibly tethered RBDs of the RBD-foldon bind ACE2 with high avidity. Approximately 20% of the P 2S trimers are in the two-RBD ‘down,’ one-RBD ‘up’ state. In mi…

Vaccinationchemistry.chemical_classificationMessenger RNACoronavirus disease 2019 (COVID-19)chemistryHigh aviditySevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)BiologyGlycoproteinVirologyCD8Transmembrane protein
researchProduct

BNT162b2 Vaccine Encoding the SARS-CoV-2 P2 S Protects Transgenic hACE2 Mice against COVID-19.

2021

BNT162b2 is a highly efficacious mRNA vaccine approved to prevent COVID-19. This brief report describes the immunogenicity and anti-viral protective effect of BNT162b2 in hACE2 transgenic mice. Prime-boost immunization with BNT162b2 elicited high titers in neutralizing antibodies against SARS-CoV-2, which correlated with viral clearance and alleviated lung lesions in these mice after viral challenge.

0301 basic medicineGenetically modified mouseSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)TransgenevirusesImmunologyefficacylcsh:Medicineimmunogenicitychallenge study03 medical and health sciences0302 clinical medicineDrug DiscoveryMedicinePharmacology (medical)030212 general & internal medicinePharmacologyMessenger RNAbiologybusiness.industrySARS-CoV-2Brief ReportImmunogenicitylcsh:RCOVID-19VirologyTiter030104 developmental biologyInfectious DiseasesmRNA vaccineImmunizationbiology.proteinAntibodybusinessVaccines
researchProduct